These trends, which are comparable to previous clinical observations (30), suggest that distinct mutations may influence could be linked to differences in metastatic tropism through variations in downstream PI3K/AKT/mTOR signaling or tumor–microenvironment interactions. This evidence concerns the gene MTOR and neoplasm.